ZIOPHARM Oncology (ZIOP) was Upgraded by Wells Fargo to ” Market Perform”. Earlier the firm had a rating of “Underperform ” on the company shares. Wells Fargo advised their investors in a research report released on Aug 10, 2016.
Many Wall Street Analysts have commented on ZIOPHARM Oncology. Shares were Reiterated by Mizuho on Jul 19, 2016 to “Neutral” and Lowered the Price Target to $ 5 from a previous price target of $7 .ZIOPHARM Oncology was Initiated by Raymond James to “Mkt Perform” on Jun 2, 2016.
On the company’s financial health, ZIOPHARM Oncology reported $-1.01 EPS for the quarter, missing the analyst consensus estimate by $ -0.90 based on the information available during the earnings call on Aug 9, 2016. Analyst had a consensus of $-0.11. The company had revenue of $1.70 million for the quarter, compared to analysts expectations of $1.48 million. The company’s revenue was up 525.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.11 EPS.
ZIOPHARM Oncology closed down -0.25 points or -4.88% at $4.87 with 12,57,172 shares getting traded on Monday. Post opening the session at $5.15, the shares hit an intraday low of $4.855 and an intraday high of $5.16 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Nov 23, 2015, Caesar J Belbel (COO, CLO, and Secretary) sold 153,333 shares at $12.84 per share price. According to the SEC, on Jun 11, 2015, Francois Lebel (Executive Vice President R&D) sold 50,000 shares at $10.12 per share price. On Jun 5, 2015, Kevin G Lafond (Vice Pres., Treasurer, & CAO) sold 57,500 shares at $9.67 per share price, according to the Form-4 filing with the securities and exchange commission.
ZIOPHARM Oncology Inc. is a biopharmaceutical company. The Company is engaged in the acquisition development and commercialization of a portfolio of cancer therapies through synthetic biology. The Company’s pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies. The Company’s clinical stage product candidate Ad-RTS-IL-12 is used with the oral activator veledimex being developed for the treatment of oncology. Ad-RTS-IL-12 in combination with veledimex uses the synthetic biology platform (gene-delivery system) to produce Interleukin-12 or IL-12 a potent naturally occurring anti-cancer protein. The Company has completed two Phase II studies evaluating Ad-RTS-IL-12 in combination with veledimex for the treatment of metastatic melanoma and for the treatment of metastatic breast cancer. The Company is also developing CAR-T Cells (Cytokine products).